TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01812291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1: Diabetes-Specific CBT (5 group sessions)
Description: Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~* Diabetes problem analysis/ definition~* Diabetes problem solving intervention~* Cognitive restructuring of diabetes problems~* Activation of personal and social resources~* Goal definition and agreement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2: Depression-Specific CBT (6 single sessions)
Description: Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~* Functional explanatory model of depression~* Cognitive restructuring of negative thoughts~* Practice of alternative beneficial thoughts~* Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 3: Referral to Psychotherapist and/or Psychiatrist
Description: Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Education
Description: Standard diabetes education and professional care.~Includes:~* Health care and specific topics (e. g. blood pressure)~* Diabetes complications~* Healthy and unhealthy foods, cooking recommendations and recipes~* Foot care: exercises, care and control, injuries, and diabetic neuropathy~* Sports, activities and exercise~* Social aspects of living with diabetes
Study: NCT04399850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis group
Description: Patients who receive hypnosis
Study: NCT01376180

Intervention type: DRUG
Intervention: Lamotrigine
Description: Administered according to the prescribing information in the locally approved label by the authorities
Study: NCT00995540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INGAP Peptide
Description: 100 mg INGAP Peptide tid subcutaneous injection for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INGAP Peptide
Description: 200 mg INGAP Peptide tid subcutaneous injection for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tid subcutaneous injection for 12 weeks
Study: NCT03430089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shz QIV 0.25 mL, 2 doses
Description: Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shz QIV 0.5 mL, 2 doses
Description: Administered intramuscularly into the deltoid muscle, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shz QIV 0.5 mL, single dose
Description: Administered intramuscularly into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shz QIV 0.5 mL, single dose
Description: Administered intramuscularly into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shz QIV 0.5 mL, single dose
Description: Administered intramuscularly into the deltoid muscle.
Study: NCT02162134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Ketorolac 30 mg IV
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Ketorolac 30 mg IV
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
Study: NCT03399435

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with bupivacaine low and epinephrine (T1)
Description: A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bupivacaine low combined with epinephrine (C1)
Description: A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
Study: NCT02162134

Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Zantac 50mg IV
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Zantac 50mg IV
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Zantac 50mg IV
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
Study: NCT00818350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNITINIB
Description: 50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
Study: NCT02391688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Study: NCT00644215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU and Mitomycin
Description: * 5-FU injection 5mg~* Mitomycin drop 0.02%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU and Mitomycin
Description: * 5-FU injection 5mg~* Mitomycin drop 0.02%
Study: NCT02009176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Aon-anatomical Hepatectomy
Description: We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
Study: NCT00583557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: IV 10mg/kg Q28 days
Study: NCT04145128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881
Description: AG-881 tablets.
Study: NCT03048708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: patients who had received treatment with bariatric surgery for medical reasons
Study: NCT01131312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thinprep
Description: Pap test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid capture 2
Description: Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
Study: NCT02657278

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arterial Revascularization surgery or Endovascular procedure
Description: Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
Study: NCT04305613

Intervention type: OTHER
Intervention: Chemoradiation
Description: Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
Study: NCT03539562

Intervention type: DRUG
Intervention: Morphine Sulfate and Promethazine
Description: Morphine sulfate and promethazine
Study: NCT00813930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INTERxVENT lifestyle modification program
Description: It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
Study: NCT02401672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
Study: NCT03399435

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bupivacaine high combined with epinephrine (C2)
Description: A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with bupivacaine low (T2)
Description: A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine low (C3)
Description: A single injection: Bupivacaine from 10 to 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine high (C4)
Description: A single injection: Bupivacaine 100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin (T3)
Description: A single injection: Neosaxitoxin will be between 1.25 and 60 µg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with epinephrine (T4)
Description: A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with bupivacaine low and epinephrine
Description: A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with bupivacaine low
Description: A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
Study: NCT03894917

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment (CGA)
Description: Assessments will be done for participants that are 65 years or older.
Study: NCT02401672

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
Study: NCT02984540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet
Description: Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to \<40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
Study: NCT01645709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02157558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: All subjects will receive 180 mg fexofenadine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
Study: NCT01463605

Intervention type: DRUG
Group type: OTHER
Intervention: Nimotuzumab
Description: Nimotuzumab 200mg,once per week,for 5 to 6 weeks
Study: NCT01916018

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and radiologic exams and blood samples
Study: NCT01398605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Different dose of exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Different dose of exercise training
Study: NCT03646513

Intervention type: DEVICE
Intervention: SMF Short Modular Femoral Hip System
Description: Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
Study: NCT00112073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: IV, Q13w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: IV, Q13w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: IV, Q13w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: IV, Q13w

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV Q13w

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV Q13w

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV Q13w

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV Q13w
Study: NCT02905526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive instant messages
Description: Contraceptive Instant messages

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mobile phone app
Description: Mobile phone app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone app
Description: Mobile phone app
Study: NCT04192097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professionalism curriculum
Description: One year training program including ten two-hours sessions about~* Knowing yourself~* Interaction with patients and their families~* Teamwork and organization with colleagues
Study: NCT01269892

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: lactose-free milk
Description: a milk without lactose

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: conventional milk
Description: a milk with lactose
Study: NCT03236103

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Recommendations
Description: The clinical recommendations will regard the following:~1. Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Optimizing hemodynamics (Mean arterial BP\>65mmHg)~5. Assessment of kidney function with serum creatinine and/or cystatin C~None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice.
Study: NCT03259035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: 6 cycles of q2weekly FOLFOX, or

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capox
Description: 4 cycles of q3weekly CAPOX
Study: NCT03407638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROUD Intervention
Description: The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
Study: NCT02545894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Description: The tasks are:~* visually tracking a picture as it moves across the computer screen~* pressing a button every time a picture is seen on the screen~* pressing a button every time a specific picture is seen on the screen~* Pressing a button every time a specific sound is heard~* Matching objects to a picture~* Matching gestures to objects~* Matching two connected objects~* Sorting objects by categories~* Matching sounds to objects~* Complete the category and odd on out with objects~* Choosing target objects by pointing~* Choosing objects to complete the category by pointing
Study: NCT02012374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Language Action Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Language Action Therapy
Study: NCT03544034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HomeTeam Toolkit
Description: A multi-component intervention (8S's)~1. Safety at home through partnership.~2. Safety risk assessment at the admission~3. Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~4. Safety tools. Cognitive tools to support patient/family after discharge~5. Safety education. Enhanced Patient/ family medication safety education~6. Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~7. Safety through learning routines across the care continuum~8. Safety assessment after discharge
Study: NCT01851057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR
Description: Problem-solving and education intervention (8 total sessions)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Only
Description: Education around epilepsy (8 total sessions)
Study: NCT04842695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture group
Description: compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture group
Description: compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
Study: NCT00723177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV411
Description: Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV411
Description: Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PCB)
Description: Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
Study: NCT04109989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HominisTM Surgical System
Description: Trans-vaginal gynecological procedures
Study: NCT00931177

Intervention type: OTHER
Intervention: weight
Description: weight and dehydration scores

Intervention type: OTHER
Intervention: weight and dehydration score
Description: weight and dehydration score
Study: NCT00245557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day.~Duration of treatment was 12 weeks.
Study: NCT03359096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic HGNS
Description: Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Subtherapeutic 'Sham' HGNS
Description: Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds
Study: NCT04130061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Membrane
Description: Epicardial application of human amniotic membrane during cardiac surgery
Study: NCT04146441

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: 1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: FOLFIRINOX Regime according to Norwegian national guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: FOLFIRINOX Regime according to Norwegian national guidelines
Study: NCT00938288

Intervention type: DRUG
Group type: OTHER
Intervention: KW-3357
Description: 50IU/mL, IV single dose
Study: NCT02294461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral